Q4 2025 Management View CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all components of our business,” reaffirming a “singular focus to build a multi-franchise business in solid tumor oncology based on the foundation of cabozantinib,

In a report released today, from Stephens maintained a Buy rating on Exelixis, with a price target of $60.00. In addition to Stephens, Exelixis also received a Buy from TD Cowen’s Yaron Werber in a report issued today. However, on the same day, Morgan Stanley maintained a Hold rating on Exelixis (NASDAQ: EXEL).

Exelixis recently advanced its oncology pipeline by submitting an FDA application for its next-generation cancer drug zanzalintinib, in combination with Roche’s Tecentriq, for metastatic colorectal cancer.

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX reduced the risk of disease progression or death by 81% ...

These innovative biotechs could have plenty of upside ahead.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans on completing the currently ...

– Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for investigation in patients with advanced solid tumors – “We are excited to share preclinical data from four of ...

Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.